Skip to main content
  • Home
  • Imaging-based Procedure-planning with OCT: Application to Clinical Practice

Imaging-based Procedure-planning with OCT: Application to Clinical Practice

Topic:
  • Prevention

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

Overview

In this session, ‘Imaging-based Procedure-planning with OCT: Application to Clinical Practice’ part of the ‘Optimising the Use of Contemporary Invasive Imaging for PCI’ series a leading faculty discuss how to optimise the use of contemporary invasive imaging for PCI in appropriate patients and present a number of case-studies in which these imaging techniques have been applied.

Optimising the Use of Contemporary Invasive Imaging for PCI aims to offer education on proper image acquisition, interpretation, and correct decision-making to optimise the use of contemporary imaging. The programme provides an overview of the current use of intravascular ultrasound (IVUS) and optical coherence tomography (OCT), the relative advantages of each technique and real-world insight from imaging experts. 

Disclosure

In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
This programme is supported by unrestricted educational grant by Abbott. The scientific programme has not been influenced in any way by the sponsors.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

The session of ‘Imaging-based Procedure-planning with OCT: Application to Clinical Practice' is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

Target Audience

This programme is intended to educate:

  • Cardiologists, interventionalists, physicians within the peripheral intervention space and imaging specialists.

Learning Objectives

The overall programme, ‘Optimising the Use of Contemporary Invasive Imaging for PCI’, endeavours to best address the following learning objectives:

  • Incorporate contemporary imaging for PCI in appropriate patients
  • Differentiate between modern imaging techniques based on clinical data
  • Recall best practices for image acquisition, interpretation and decision-making
  • Interpret image data and make clinical decisions generated from existing case study data
Register now Log in

Module

Title

Duration

Speakers

Session 1 Plenary Presentation; Light Lab Data, MLD, MAX 27 minutes Natalia Pinilla-Echeverri Matheen A Khuddus Jacob Odenstedt
Session 2 Case Studies 29 minutes Natalia Pinilla-Echeverri Matheen A Khuddus Jacob Odenstedt
Session 3 Faculty discussion 20 minutes Natalia Pinilla-Echeverri Matheen A Khuddus Jacob Odenstedt
Session 1.

Plenary Presentation; Light Lab Data, MLD, MAX

Duration: 27 minutes

Speakers: Natalia Pinilla-Echeverri Matheen A Khuddus Jacob Odenstedt

Session 2.

Case Studies

Duration: 29 minutes

Speakers: Natalia Pinilla-Echeverri Matheen A Khuddus Jacob Odenstedt

Session 3.

Faculty discussion

Duration: 20 minutes

Speakers: Natalia Pinilla-Echeverri Matheen A Khuddus Jacob Odenstedt

Chair

Natalia Pinilla-Echeverri

Dr Pinilla is originally from Colombia and received her MD from Universidad de Caldas in Manizales, Colombia.

View full profile

Speaker

Matheen A Khuddus

The Cardiac and Vascular Institute, Gainesville, FL

View full profile

Speaker

Jacob Odenstedt

View full profile

1.00 European Board for Accreditation in Cardiology (EBAC)

Related Courses

Imaging vs Angiography-led PCI: An Overview for DES Implantation
  • 1.00 EBAC

Learning objectives

  • Incorporate contemporary imaging for PCI in appropriate patients
  • Differentiate between modern imaging techniques based on clinical data
  • Recall best practices for image acquisition, interpretation and decision-making
  • Interpret image data and make clinical decisions generated from existing case study data
See more
Imaging vs angiography-led PCI: What does success look like?
  • 1.00 EBAC

Learning objectives

  • Incorporate contemporary imaging for PCI in appropriate patients
  • Differentiate between modern imaging techniques based on clinical data
  • Recall best practices for image acquisition, interpretation and decision-making
  • Interpret image data and make clinical decisions generated from existing case study data
See more
ADVANCES IN IMAGING: OPTIMISING MR AND CT IN DAILY PRACTICE
  • 2.00 EBAC

Learning objectives

  • Interpret existing clinical and meta data for use of pre-procedural, image-aided ablation in ventricular arrhythmias
  • Identify where pre-procedural imaging may complement the current ablation workflow in ventricular arrhythmias
  • Recall the clinical benefits of quantitative, MRI-based approaches to evaluate ischaemia
  • Apply quantitative CMR imaging to complement existing procedural workflows in revascularisation procedures
See more
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
  • Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
  • Assess the interrelationships linking diabetes, HF and CVD.
  • Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
  • Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more
Dual antiplatelet therapy for acute stroke and TIA
  • 1.00 EBAC

Learning objectives

  • To highlight the continued high unmet need for strategies to prevent stroke or death for patients experiencing acute stroke or TIA
  • To outline the guidelines on the use of dual antiplatelet therapy for patients presenting with acute stroke or TIA
  • To examine recent evidence from clinical trials on novel strategies for improving outcomes for patients presenting with acute stroke or TIA and how these data and insights can be applied in clinical practice
See more
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
  • differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
  • apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
  • assess the interrelationships linking diabetes, HF and CVD;
  • interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more